Literature DB >> 28941475

Melanocytes: Target Cells of an HLA-C*06:02-Restricted Autoimmune Response in Psoriasis.

Jörg Christoph Prinz1.   

Abstract

HLA-C*06:02 is the main psoriasis risk allele. By the unbiased analysis of a Vα3S1/Vβ13S1 T-cell receptor from pathogenic psoriatic CD8+ T cells, we had recently proven that HLA-C*06:02 directs an autoimmune response against melanocytes through autoantigen presentation in psoriasis and identified ADAMTSL5 as a melanocyte autoantigen. We concluded that psoriasis is based on a melanocyte-specific immune response and that HLA-C*06:02 may predispose to psoriasis via this newly identified autoimmune pathway. Understanding this pathway, however, requires more detailed explanation. It is based on the fact that an HLA class I-restricted autoreactive CD8+ T-cell response must be directed against a particular target cell type, because HLA class I molecules present peptide antigens generated from cytoplasmic (i.e., intracellular) proteins. This review summarizes the findings on the melanocyte-specific autoimmune response in the context of the immune mechanisms related to HLA function and T-cell receptor-antigen recognition. Identifying melanocytes as target cells of the psoriatic immune response now explains psoriasis as a primary autoimmune skin disease.
Copyright © 2017 The Author. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28941475     DOI: 10.1016/j.jid.2017.05.023

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  16 in total

1.  The Quest for Psoriasis Autoantigens: Genetics Meets Immunology in the Melanocyte.

Authors:  James T Elder
Journal:  J Invest Dermatol       Date:  2017-10       Impact factor: 8.551

Review 2.  Psoriasis: Past, Present, and Future.

Authors:  Allison C Billi; Johann E Gudjonsson; John J Voorhees
Journal:  J Invest Dermatol       Date:  2019-11       Impact factor: 8.551

3.  Past and Present Behçet's Disease Animal Models.

Authors:  Jermilia Charles; Francis J Castellino; Victoria A Ploplis
Journal:  Curr Drug Targets       Date:  2020       Impact factor: 3.465

4.  Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy.

Authors:  Marco Galluzzo; Simone D'Adamio; Elena Campione; Luca Bianchi; Marina Talamonti
Journal:  Mol Diagn Ther       Date:  2018-12       Impact factor: 4.074

Review 5.  The Immunogenetics of Psoriasis and Implications for Drug Repositioning.

Authors:  Xuan Xu; Hong-Yu Zhang
Journal:  Int J Mol Sci       Date:  2017-12-08       Impact factor: 5.923

Review 6.  Adaptive and Innate Immunity in Psoriasis and Other Inflammatory Disorders.

Authors:  Michael P Schön
Journal:  Front Immunol       Date:  2019-07-26       Impact factor: 7.561

Review 7.  Neutrophils in Psoriasis.

Authors:  Chih-Chao Chiang; Wei-Jen Cheng; Michal Korinek; Cheng-Yu Lin; Tsong-Long Hwang
Journal:  Front Immunol       Date:  2019-10-09       Impact factor: 7.561

Review 8.  Psoriasis and Co-morbidity.

Authors:  Mina Amin; Erica B Lee; Tsen-Fang Tsai; Jashin J Wu
Journal:  Acta Derm Venereol       Date:  2020-01-30       Impact factor: 3.875

Review 9.  The Woronoff Ring in Psoriasis and the Mechanisms of Postinflammatory Hypopigmentation.

Authors:  Jörg C Prinz
Journal:  Acta Derm Venereol       Date:  2020-01-30       Impact factor: 3.875

Review 10.  Human Leukocyte Antigen-Class I Alleles and the Autoreactive T Cell Response in Psoriasis Pathogenesis.

Authors:  Jörg Christoph Prinz
Journal:  Front Immunol       Date:  2018-04-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.